UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News:
Orexo (STO:ORX):
Unless otherwise stated in this report, all data refers to the group. Figures in parentheses are for the corresponding periods in 2010.
POSITIVE DEVELOPMENT IN ABSTRAL® SALES AND OREXO’S PROPRIETARY PROGRAMS WHILE THE OX-CLI AND OX-ESI PROJECTS ARE ABORTED
